Anlon Healthcare Ltd
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).[1]
- Market Cap ₹ 736 Cr.
- Current Price ₹ 13.8
- High / Low ₹ 17.3 / 8.70
- Stock P/E 25.8
- Book Value ₹ 4.33
- Dividend Yield 0.00 %
- ROCE 20.8 %
- ROE 18.4 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 220 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 120 | 172 | |
| 88 | 124 | |
| Operating Profit | 32 | 48 |
| OPM % | 27% | 28% |
| 0 | 0 | |
| Interest | 4 | 4 |
| Depreciation | 2 | 2 |
| Profit before tax | 27 | 43 |
| Tax % | 24% | 32% |
| 21 | 29 | |
| EPS in Rs | 0.51 | 0.54 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 40 | 53 |
| Reserves | 41 | 177 |
| 67 | 44 | |
| 34 | 100 | |
| Total Liabilities | 181 | 374 |
| 23 | 58 | |
| CWIP | 0 | 0 |
| Investments | 1 | 1 |
| 158 | 315 | |
| Total Assets | 181 | 374 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Net Cash Flow | ||
| Free Cash Flow | ||
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 228 | 220 |
| Inventory Days | 246 | 393 |
| Days Payable | 96 | 147 |
| Cash Conversion Cycle | 377 | 467 |
| Working Capital Days | 294 | 417 |
| ROCE % | 21% |
Insights
In beta| Mar 2018 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Total Commercialized Products Number ・Standalone data |
|
|||
| Actual Production Volume MT ・Standalone data |
||||
| Capacity Utilization % ・Standalone data |
||||
| Export Contribution to Revenue % ・Standalone data |
||||
| Installed Production Capacity MTPA ・Standalone data |
||||
| Products in R&D Pipeline (Pilot/Lab) Number ・Standalone data |
||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Copy of newspaper publication dated May 30, 2026 regarding publication of extract of Audited Financial Results (Standalone and Consolidated) for Quarter and Year ended 31st …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - Audited Q4/FY26 results: consolidated income ₹172.22 Cr, PAT ₹29.09 Cr; Bizotic Lifescience acquired.
- Considered, Approved And Taken On Record Audited Financial Results For The Quarter And Year Ended 31St March, 2026 2d
-
Board Meeting Outcome for To Consider And Approve Financial Results For The Quarter And Year Ended March 31, 2026
2d - Board approved FY26 audited standalone and consolidated results; auditor issued unmodified opinion.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 May
Concalls
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
Business Profile[1]
Anlon Healthcare is a chemical manufacturing company engaged in:
a) Pharmaceutical Intermediates – high-purity intermediates used as raw material/starting material in APIs.
b) Active Pharmaceutical Ingredients (APIs) – raw material for finished dosage formulations (tablets, capsules, ointments, syrups, etc.), nutraceuticals, personal care, and veterinary products.
c) It recently expanded into custom manufacturing services for complex/novel chemical compounds, including high-purity chemicals.